Annotation Detail

Information
Associated Genes
ATRX
Associated Variants
ATRX UNDEREXPRESSION ( ENST00000373344.11 )
ATRX UNDEREXPRESSION ( ENST00000373344.11 )
Associated Disease
malignant astrocytoma
Source Database
CIViC Evidence
Description
A retrospective tumor sample study found that the loss of ATRX expression (less than 10% of nuclei) in IDH-mutant astrocytomas treated with temozolomide or a combination of procarbazine, lomustine and vincristine was associated with a greater time to treatment failure (55.6 months vs. 31.8 months; P = .0168) and a greater progression-free survival (37.1 months vs. 18.1 months; P = .038).
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1647
Gene URL
https://civic.genome.wustl.edu/links/genes/525
Variant URL
https://civic.genome.wustl.edu/links/variants/648
Rating
3
Evidence Type
Predictive
Disease
Astrocytoma
Evidence Direction
Supports
Drug
Procarbazine,Lomustine,Vincristine,Temozolomide
Evidence Level
B
Pubmed
23904111
Drugs
Drug NameSensitivitySupported
LomustineN/Atrue
ProcarbazineN/Atrue
TemozolomideN/Atrue
VincristineN/Atrue